Legacy Capital Wealth Partners’s AbbVie ABBV Stock Holding History

Legacy Capital Wealth Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$904K	Sell	3,593 -297	-8%	-$63.9K	0.17%	116
2026 Q1	$846K	Sell	3,890 -144	-4%	-$31.9K	0.17%	124
2025 Q4	$922K	Sell	4,034 -496	-11%	-$113K	0.2%	106
2025 Q3	$1.05M	Sell	4,530 -67	-1%	-$13.6K	0.23%	93
2025 Q2	$853K	Buy	4,597 +295	+7%	+$54.8K	0.19%	105
2025 Q1	$901K	Buy	4,302 +152	+4%	+$29.5K	0.22%	93
2024 Q4	$737K	Sell	4,150 -319	-7%	-$58.6K	0.18%	111
2024 Q3	$883K	Buy	4,469 +371	+9%	+$69.2K	0.18%	114
2024 Q2	$703K	Buy	+4,098	New	+$679K	0.18%	113
2024 Q1	–	Sell	-3,447	Closed	-$534K	–	113
2023 Q4	$534K	Buy	3,447 +4	+0.1%	+$583	0.15%	136
2023 Q3	$513K	Buy	+3,443	New	+$505K	0.14%	141
2023 Q2	–	Sell	-3,017	Closed	-$481K	–	42
2023 Q1	$481K	Buy	+3,017	New	+$461K	0.13%	140
2021 Q2	–	Sell	-1,953	Closed	-$211K	–	25
2021 Q1	$211K	Buy	+1,953	New	+$209K	0.09%	77

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Legacy Capital Wealth Partners's ABBV Position: Q2 2026 in Review

Legacy Capital Wealth Partners reduced its AbbVie (ABBV) stake by 7.6% in Q2 2026, selling an estimated $63.9K and leaving 3,593 shares worth $904K. The position accounts for 0.17% of the portfolio, ranked #116.

Legacy Capital Wealth Partners first reported a position in ABBV in Q1 2021 and has held it in 13 quarters since. The position peaked at $1.05M in Q3 2025. 4,206 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Legacy Capital Wealth Partners held 3,593 shares of AbbVie worth $904K as of Q2 2026.
Legacy Capital Wealth Partners sold 297 AbbVie shares in Q2 2026, an estimated $63.9K.
AbbVie made up 0.17% of Legacy Capital Wealth Partners's portfolio in Q2 2026, its #116 holding.
Legacy Capital Wealth Partners first reported a position in AbbVie in Q1 2021 and has held it in 13 quarters since.
Legacy Capital Wealth Partners's AbbVie position peaked at $1.05M in Q3 2025.
4,206 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Legacy Capital Wealth Partners's 13F filing for Q2 2026, filed 12 Aug 2026.